Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout

Journal of Clinical Rheumatology

Volumn 6, Issue 5, 2000, Pages 266-268

  Vazquez Mellado, J ^a   Guzman Vazquez, S ^a   Cazarin Barrientos, J ^a   Gomez Rios, V ^a   Burgos Vargas, R ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Allopurinol; Allopurinol hypersensitivity syndrome; Desensitization to allopurinol; Gout; Gout therapy

Indexed keywords

ALLOPURINOL; ANTIRHEUMATIC AGENT; BENZOBROMARONE; COLCHICINE; DEXAMETHASONE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONJUNCTIVITIS; CREATININE BLOOD LEVEL; DESENSITIZATION; DRUG HYPERSENSITIVITY; EOSINOPHILIA; GOUT; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; RASH; SYMPTOM; TREATMENT OUTCOME;

EID: 0033770793     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-200010000-00006     Document Type: Article

References (13)

1. Severe allopurinol toxicity
2. Toxic epidemal necrolysis, azotemia, and death after allopurinol therapy
3. The allopurinol hypersensitivity syndrome
4. Allopurinol hypersensitivity syndrome: A review
5. Allopurinol hypersensitivity in a patient with severe chronic tophaceous gout
6. Desensitization to allopurinol
7. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions
8. Allopurinol sensitivity in a patient with chronic tophaceous gout: Success of intravenous desensitization after failure of oral desensitization
9. Desensitization to allopurinol in patients with gout and cutaneous reactions
10. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity
11. Drug induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)
12. Efficacy and safety of desensitization to allopurinol following cutaneous reactions
13. Efficacy of allopurinol and benzobromarone for the control of hyperuricemia: A pathogenic approach to the treatment of primary chronic gout